ADHD Therapeutics Market 2018 To Expand Steadily In The Coming Years | Exclusive Foreseen by MRFR up to 2024

“ADHD Therapeutics Market”
The Global ADHD Therapeutics Market Report is Recently Published By Market Research Future Firm. Report include market exclusive analysis on the basis of industry size, recent trends, demand supply and growth of market. Market analysis is available on MarketResearchFuture.com uniquely by 80+ pages information, 30+ tables and 30+ figures exclusively.

Key Players for Global ADHD Therapeutics Market

The prominent players profiled by MRFR in the report on the global ADHD therapeutics market are Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical and others.

Global ADHD Therapeutics Market Competitive Analysis 

The global ADHD Therapeutics market is a fragmented market with a large number of players. Product development strategy has been curtailed by the excellent efficiency and efficacy of drugs. However, the rise of drug resistance has opened doors for new drug development and is an opportunity for a new market leader. The rise of spurious and counterfeit medicines have reduced the total market revenues and at the same time displaced standard drugs off the market. Key Players are focusing on innovative products with minimum adverse effects, as well as targeting emerging applications to leverage growth opportunities.

Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1573

Industry Updates:

In August 2018, Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics Inc., has received FDA approval for the New Drug Application for Jornay PM (methylphenidate) which was formerly known as HLD200 which is used for the treatment of ADHD in patients of the age six and older

In August 2018, FDA has issued a Complete Response Letter (CRL) to Sunovion Pharmaceutical asking for further clinical data to evaluate the efficacy of dasotraline, the ADHD drug.

ADHD Therapeutics Market – Sketch

Acknowledging the value this market is garnering currently and the growth prospect the market is demonstrating worldwide, Market Research Future (MRFR), recently published a brilliant study report giving out the complete market prognosis up till 2024. According to MRFR, the Global ADHD Therapeutics market is expected to grow exponentially, registering a phenomenal CAGR during the forecasted period (2017 -2024).

Other factors propelling the market growth include increasing risk factors, proliferating healthcare sector along with the increasing number of advanced HC facilities and the increasing awareness about the treatment method. Improving economic conditions that enable access to the quality life & to the improved healthcare worldwide are providing impetus to the market growth.

Technological advancements transpired in the medical science backed by the substantial investments in the R&D activities for the innovation & development of novel treatments & medicines, foster the market growth of ADHD Therapeutics, excellently.

On the other hand, factors such as incidents of drug resistance, and unmet clinical needs, coupled with the high cost associated with the treatments are expected to restrict the market growth. Nevertheless, the emergence of Biosimilars would certainly avail affordable, cost- effective medical products, which will in turn, propel the market growth of ADHD Therapeutics.

ADHD Therapeutics Market Drivers and Restraints:

The symptoms of ADHD such as lack of attention, hyperactivity and impulsivity hamper proper functioning and development of an individual. Increasing awareness regarding neurodevelopmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth of the global ADHD therapeutics market.

Changing lifestyles and value systems along with the factors like genetic inheritance and premature birth are resulting to the rise in prevalence of ADHD among children in the age group of 4-17 years, which in turn is propelling the growth of the global ADHD therapeutics market. Increasing availability of online platforms for therapists that assure anonymity of the patient is inclining more individuals towards undergoing therapeutic treatment for ADHD, which in turn is fueling the expansion of the global ADHD therapeutics market

However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.

Regional Analysis:

Geographically, the global ADHD therapeutics market is segmented into four major regions such as North America, Europe, Asia Pacific and the Middle East and Africa. The ADHD therapeutics market in the North America region accounts for the dominant share in the global ADHD therapeutics market owing to the increasing prevalence of ADHD in the children and high healthcare expenditure by the population in this region. The ADHD therapeutics market in the Europe region is projecting significant growth owing to the increased research and development for the introduction of more effective drugs in this region. The Asia Pacific region is anticipated to grow at a notable pace in the coming years due to increased awareness regarding ADHD and its available treatments. Whereas, the Middle East and Africa region is projecting steady growth in the global ADHD market owing to the low awareness and poor primary health care in the underdeveloped areas of this region.

Segments for Global ADHD Therapeutics Market

The global ADHD therapeutics market has been segmented on the basis of drug type and distribution channel. Based on drug type, the ADHD therapeutics market is segmented into stimulants and non-stimulants. The stimulants segment is sub-segmented into amphetamine, methylphenidate, dextroamphetamine, lisdexamfetamine and others. The non-stimulants segment is sub-segmented into atomoxetine, bupropion, guanfacine and clonidine

Based on distribution channel, the ADHD therapeutics market is segmented into hospitals, clinics, pharmacies, research laboratories and others.

Do You Have Specific Requirement? Ask To Our Experts@ https://www.marketresearchfuture.com/enquiry/1573

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573